205 related articles for article (PubMed ID: 33750116)
1. Selective CRAF Inhibition Elicits Transactivation.
Morgan CW; Dale IL; Thomas AP; Hunt J; Chin JW
J Am Chem Soc; 2021 Mar; 143(12):4600-4606. PubMed ID: 33750116
[TBL] [Abstract][Full Text] [Related]
2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
3. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
Yuan J; Ng WH; Yap J; Chia B; Huang X; Wang M; Hu J
J Biol Chem; 2018 Sep; 293(37):14276-14284. PubMed ID: 30030377
[TBL] [Abstract][Full Text] [Related]
4. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
5. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
[TBL] [Abstract][Full Text] [Related]
7. Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1
Kim J; Choi B; Im D; Jung H; Moon H; Aman W; Hah JM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1314-1320. PubMed ID: 31307243
[TBL] [Abstract][Full Text] [Related]
8. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP; Marais R
Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
[TBL] [Abstract][Full Text] [Related]
9. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
10. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
11. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition.
Jung H; Kim J; Im D; Moon H; Hah JM
Bioorg Med Chem Lett; 2019 Feb; 29(4):534-538. PubMed ID: 30630714
[TBL] [Abstract][Full Text] [Related]
13. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.
Riaud M; Maxwell J; Soria-Bretones I; Dankner M; Li M; Rose AAN
Nat Rev Cancer; 2024 Feb; 24(2):105-122. PubMed ID: 38195917
[TBL] [Abstract][Full Text] [Related]
14. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
[TBL] [Abstract][Full Text] [Related]
15. Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex.
Vasta JD; Michaud A; Zimprich CA; Beck MT; Swiatnicki MR; Zegzouti H; Thomas MR; Wilkinson J; Crapster JA; Robers MB
Cell Chem Biol; 2023 Nov; 30(11):1354-1365.e6. PubMed ID: 37643616
[TBL] [Abstract][Full Text] [Related]
16. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
17. CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
Venkatanarayan A; Liang J; Yen I; Shanahan F; Haley B; Phu L; Verschueren E; Hinkle TB; Kan D; Segal E; Long JE; Lima T; Liau NPD; Sudhamsu J; Li J; Klijn C; Piskol R; Junttila MR; Shaw AS; Merchant M; Chang MT; Kirkpatrick DS; Malek S
Cell Rep; 2022 Feb; 38(6):110351. PubMed ID: 35139374
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
19. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
Wang L; Zhu G; Zhang Q; Duan C; Zhang Y; Zhang Z; Zhou Y; Lu T; Tang W
Org Biomol Chem; 2017 Apr; 15(16):3455-3465. PubMed ID: 28368067
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]